Therefore, before using CXCR3 variants as potential anti-tumor targets, a better understanding of the biology of CXCR3 variants is needed to clarify their exact signaling pathways and cellular responses in the TME to lay a solid foundation for precise or combination tumor treatment. The gene discussed is CXCR3; the disease is neoplasm.